ResearchAndMarkets forecasts 7.8% yearly growth from $5.13 billion in 2025, led by functional foods and sports nutrition, with Asia Pacific holding 34.5% of the market.
Recap by typeshit. Full story at Yahoo Finance.
12:50
Alex Wallace, who bills himself as a peptide expert, gives his response to what Dr. Mike has said about peptides. Details beyond the title are thin.
A search result from Polskie Radio on the approval status of tirzepatide for weight loss, with no further detail provided beyond the question itself.
A Facebook post credits Novo Nordisk's GLP-1 drugs with strong results in obesity and type 2 diabetes, plus lower risk of other conditions.
Lilly's tirzepatide shot Zepbound now has FDA approval in a KwikPen format for weight management. Tap through for details on the new pen.
A local TV health segment on safety when using peptide therapy and GLP-1 drugs, aimed at men's health.
Ascletis says its lead amylin tablet ASC36o lasted about 7 days in monkeys and is now in a US Phase I study, with human PK data expected by the end of 2026.
Loading…